SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63369 356 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
62649Damn, Joe Springer's going off on Remi tonight haha calling him spineless. Mghettogoulash-7/1/2024
62648more from Nachtrab ..... x.complhky3465-6/29/2024
62647detailed review of recent SAVA debacle by Matt Nachtrab: x.comscorman116/29/2024
62646Ok, that answer means I will not be sending you a payment for legal advice.jargonweary16/28/2024
62645Yes, and it also says something about those who insist on referring to him by hijargonweary-6/28/2024
62644It was all that could be said that would not put the company in legal jeopardy. Fitzhughlaw26/28/2024
62643I'm with you on being mystified (and repulsed) by those who want to give himFitzhughlaw16/28/2024
62642Did you like the company's short and sweet statement?plhky3465-6/28/2024
62641Not sure about that issue of notification. What I know about the grand jury procFitzhughlaw16/28/2024
62640And PS: Cudos for not referring to the CEO by his first name…as if we are all bjargonweary-6/28/2024
62639Wouldn’t Wang have had to have been notified that he was a target of the grand jjargonweary16/28/2024
62638Agree with you on there being a critical distinction. Although I never practicedFitzhughlaw36/28/2024
62637It appears to be about NIH funding some time back and not about the FDA trials wjargonweary66/28/2024
62636re: SAVA Well, that puts a serious crimp in my investment thesis.... "Caerickerickson16/28/2024
62635seekingalpha.comOlecranon-6/28/2024
62634stockdoc: are you still of the opinion that SAVA is a longshot to get FDA approplhky3465-6/26/2024
62633ALT: Well, that fizzled out.... Not surprising I suppose.erickerickson-6/24/2024
62632Look at Altimmune go... Apparently this is the driver today... Altimmune Preserickerickson-6/24/2024
62631"ELEVIDYS is already on the market and priced at $3.2M." Well, it turerickerickson16/22/2024
62630"The approval expands the market for Elevidys by more than tenfold, Leerinkghettogoulash16/22/2024
62629Keep in mind that the cost of these therapies is based largely on how much they ghettogoulash-6/22/2024
62628ELEVIDYS is already on the market and priced at $3.2M. In any case, I'm morghettogoulash-6/22/2024
62627Is that in the US or world wide? My friend at WF told me Roche, who is responsibEMU2-6/21/2024
62626re SRPT possibilities: That assumes over $2M/child though, see post # 61818. Iterickerickson16/21/2024
62625I think Stockdoc's target is $50-100B. [graphic]ghettogoulash16/21/2024
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News